º£½ÇÉçÇø

Ground-breaking Lipid Nanoparticles, patented for efficient delivery of RNA-based vaccines and therapeutics, offer long-term stability at ambient temperatures, eliminating the need for costly cold-chain storage.

This innovation ensures high efficacy for at least 12 months, whether in aqueous or powder form, even in tropical climates reaching up to 40°C. With a validation study underway with a world-leading pharmaceutical company, our spinout aims to license-out and co-develop our technologies with RNA vaccines and therapeutics developers.

Media:

Imperiaus | Research groups | º£½ÇÉçÇø

GSK and Imperiato eliminate costly cold-chain storage of RNA vaccines | ImperiaNews | º£½ÇÉçÇø

Imperiaand GSK extend collaboration to tackle global vaccine cold-chain limits | ImperiaNews | º£½ÇÉçÇø